Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber

New England Journal of Medicine, 2005

Institut Jules Bordet, European Institute of Oncology, McGill University, Institute of Oncology Research, Ludwig-Maximilians-Universität München, Klinik für Frauenheilkunde, Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale dei Tumori, Hebron University, Geelong Hospital, Philipps University of Marburg, Western General Hospital, National Health Service, Pontifícia Universidade Católica do Rio Grande do Sul, Medical University of Vienna, National Taiwan University Hospital, Rigshospitalet, Tel Aviv Sourasky Medical Center, Russian Cancer Research Center NN Blokhin, National Institute of Oncology, Heinrich Heine University Düsseldorf, Aichi Cancer Center, University Medical Center Hamburg-Eppendorf, Klinik und Poliklinik für Neurologie, BC Cancer Agency, Klinikum Kassel, Roche (Switzerland), Breast International Group, Université Libre de Bruxelles, Dana-Farber Cancer Institute

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

5080

Citations

View on Google Scholar

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Abstract

Journal Details

Join JournalsHub

Welcome Back